Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome
Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome. // Continence. – URL: https://www.sciencedirect.com/science/article/pii/S2772973726009343?dgcid=rss_sd_all
Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome. Continence. https://www.sciencedirect.com/science/article/pii/S2772973726009343?dgcid=rss_sd_all
“Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome.” Continence.
@article{article102701,
title = {Assessment of the risk of anti-VEGF treatment for chorioretinal disease among patients using mirabegron versus anticholinergics for overactive bladder syndrome},
journal = {Continence},
url = {https://www.sciencedirect.com/science/article/pii/S2772973726009343?dgcid=rss_sd_all}
}